comparemela.com

Latest Breaking News On - Drug adverse event - Page 2 : comparemela.com

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Evolving testingTreatment strategiesMetastatic colorectal cancerClinical trial data with tucatinibColorectal cancerHer2 positiveHer2 crcHer2 targetedHer2 therapyHer2 amplificationMountaineer trialMountaineer studyMountaineer 03Combination therapyAsco 2023Asco annual meeting novel therapy

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Amir fathiResistance profileMenin inhibitor ziftomenibAdults withAcute myeloid leukemiaNpm1 mutationsRelapsed refractory amlNovel therapyClinical trialSafety profileAdverse eventsDrug adverse eventMrd testingMinimal residual diseaseMenin inhibitorsMenin inhibition

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Elias jabbourFirst reportComparing ponatinibNewly diagnosedAcute lymphocytic leukemiaCall cancerAll leukemiaPh positiveOph allTyrosine kinase inhibitorsTki therapyCombination therapyBcr ablPonatinib dosePonatinib dosingComplete response

Practical Considerations for Utilizing Second-Line Therapy in RR DTC

Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.

Treatment approachesSequencing strategiesDifferentiated thyroid cancerUtilizing second line therapyThyroid cancerDtc cancerRadioiodine refractory dtcRr dtcRai refractoryRadioactive iodine refractorySecond line therapySecond line treatmentCabozantinib formulationCabozantinib dosingAdverse eventsDrug adverse event

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Neoadjuvant durvalumabJohn heymachAdjuvant durvalumabPartnership withNon small cell lung cancerEarly stage lung cancerEarly stage nsclcDurvalumab therapyOverall survivalProgression free survivalEvent free survivalPathologic complete responsePd l1 expressionPd l1 levelAdverse eventsDrug adverse event

vimarsana © 2020. All Rights Reserved.